Vitamin C protects against cisplatin-induced nephrotoxicity and damage without reducing its effectiveness in C57BL/6 mice xenografted with lewis lung carcinoma

Nutrition and Cancer

Volumn 66, Issue 7, 2014, Pages 1085-1091

  Chen, Ming Feng ^a   Yang, Chih Min ^b   Su, Cheng Ming ^b   Hu, Miao Lin ^b  

^a E DA HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CARBONYL DERIVATIVE; CISPLATIN; CREATININE; GLUTATHIONE; GLUTATHIONE DISULFIDE; ANTINEOPLASTIC AGENT;

ADVERSE DRUG REACTION; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; C57BL 6 MOUSE; CANCER INHIBITION; CREATININE BLOOD LEVEL; DRUG INDUCED NEPHROTOXICITY; KIDNEY INJURY; LEWIS CARCINOMA; LIPID PEROXIDATION; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; RENAL PROTECTION; TUMOR XENOGRAFT; UREA NITROGEN BLOOD LEVEL; ANIMAL; BLOOD; C57BL MOUSE; CARCINOMA, LEWIS LUNG; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG SCREENING; KIDNEY; KIDNEY DISEASES; LIVER; METABOLISM; PATHOLOGY; PROTEIN CARBONYLATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ASCORBIC ACID; BLOOD UREA NITROGEN; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CISPLATIN; CREATININE; GLUTATHIONE; KIDNEY; KIDNEY DISEASES; LIPID PEROXIDATION; LIVER; MALE; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; PROTEIN CARBONYLATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908139804     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2014.948211     Document Type: Article

References (53)

1. Giaccone G.: Clinical perspectives on platinum resistance. Drugs 59 (Suppl 4), 9-17; discussion 37-38, 2000.
2. Rosenberg B.: Fundamental studies with cisplatin. Cancer 55, 2303-23l6, 1985.
3. Arany I. and Safirstein RL.: Cisplatin nephrotoxicity. Semin Nephrol 23, 460-464, 2003.
4. Ito Y., Arahata Y., Goto Y., Hirayama M., Nagamutsu M, et al.: Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. Am J Neuroradiol 19, 415-417, 1998.
5. Ekborn A., Lindberg A., Laurell G., Wallin I., Eksborg S, et al.: Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig. Cancer Chemother Pharmacol 51, 36-42, 2003.
6. Kuhlmann MK., Horsch E., Burkhardt G., Wagner M., and Kohler H.: Reduction of cisplatin toxicity in cultured renal tubular cells by the bioflavonoid quercetin. Arch Toxicol 72, 536-540, 1998.
7. Jiang M., Wei Q., Pabla N., Dong G., Wang CY, et al.: Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol 73, 1499-1510, 2007.
8. Somani SM., Husain K., Whitworth C., Trammell GL., Malafa M, et al.: Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: antioxidant defense system. Pharmacol Toxicol 86, 234-241, 2000.
9. Eipper BA. and Mains RE.: The role of ascorbate in the biosynthesis of neuroendocrine peptides. Am J Clin Nutr 54 (6, Suppl), 1153S-1156S, 1991.
10. Goldschmidt MC.: Reduced bactericidal activity in neutrophils from scorbutic animals and the effect of ascorbic acid on these target bacteria in vivo and in vitro. Am J Clin Nutr 54 (6, Suppl), 1214S-1220S, 1991.
11. Kojima S., Yamaguchi H., Morita K., and Ueno Y.: Inhibitory effect of sodium 5,6-benzylidene ascorbate (SBA) on the elevation of melanin biosynthesis induced by ultraviolet-A (UV-A) light in cultured B-16 melanoma cells. Biol Pharm Bull 18, 1076-1080, 1995.
12. Penn ND., Purkins L., Kelleher J., Heatley RV., Mascie-Taylor BH, et al.: The effect of dietary supplementation with vitamins A, C and E on cell-mediated immune function in elderly long-stay patients: a randomized controlled trial. Age Ageing 20, 169-174, 1991.
13. Rebouche CJ.: Ascorbic acid and carnitine biosynthesis. Am J Clin Nutr 54 (6, Suppl), 1147S-1152S, 1991.
14. Speit G., Wolf M., and Vogel W.: The SCE-inducing capacity of vitamin C: investigations in vitro and in vivo. Mutat Res 78, 273-278, 1980.
15. Stich HF., Karim J., Koropatnick J., and Lo L.: Mutogenic action of ascorbic acid. Nature 260, 722-724, 1976.
16. Benade L., Howard T., and Burk D.: Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1,2,4,-triazole. Oncology 23, 33-43, 1969.
17. Fujita K., Shinpo K., Yamada K., Sato T., Niimi H, et al.: Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs. Cancer Res 42, 309-316, 1982.
18. Okunieff P. and Suit HD.: Toxicity, radiation sensitivity modification, and combined drug effects of ascorbic acid with misonidazole in vivo on FSaII murine fibrosarcomas. J Natl Cancer Inst 79, 377-381, 1987.
19. Henson DE., Block G., and Levine M.: Ascorbic acid: biologic functions and relation to cancer. J Natl Cancer Inst 83, 547-550, 1991.
20. Ajith TA., Abhishek G., Roshny D., and Sudheesh NP.: Co-supplementation of single and multi doses of vitamins C and E ameliorates cisplatin-induced acute renal failure in mice. Exp Toxicol Pathol 61, 565-571, 2009.
21. Antunes LM., Darin JD., and Bianchi MD.: Protective effects of vitamin c against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacol Res 41, 405-411, 2000.
22. Atasayar S., Gurer-Orhan H., Orhan H., Gurel B., Girgin G, et al.: Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats. Exp Toxicol Pathol 61, 23-32, 2009.
23. De Martinis BS. and Bianchi MD.: Effect of vitamin C supplementation against cisplatin-induced toxicity and oxidative DNA damage in rats. Pharmacol Res 44, 317-320, 2001.
24. Maliakel DM., Kagiya TV., and Nair CK.: Prevention of cisplatin-induced nephrotoxicity by glucosides of ascorbic acid and alpha-tocopherol. Exp Toxicol Pathol 60, 521-527, 2008.
25. Weijl NI., Elsendoorn TJ., Lentjes EG., Hopman GD., Wipkink-Bakker A, et al.: Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer 40, 1713-1723, 2004.
26. Padayatty SJ., Sun H., Wang Y., Riordan HD., Hewitt SM, et al.: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140, 533-537, 2004.
27. Chen MF., Yang CM., Su CM., Liao JW., and Hu ML.: Inhibitory effect of vitamin C in combination with vitamin K3 on tumor growth and metastasis of Lewis lung carcinoma xenografted in C57BL/6 mice. Nutr Cancer 63, 1036-1043, 2011.
28. Johnsson A. and Wennerberg J.: Amifostine as a protector against cisplatin-induced toxicity in nude mice. Acta Oncol 38, 247-253, 1999.
29. Tomayko MM. and Reynolds CP.: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24, 148-154, 1989.
30. Reznick AZ. and Packer L.: Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 233, 357-363, 1994.
31. Tietze F.: Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27, 502-522, 1969.
32. Ajith TA., Usha S., and Nivitha V.: Ascorbic acid and alpha-tocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice: a comparative study. Clin Chim Acta 375, 82-86, 2007.
33. Appenroth D., Frob S., Kersten L., Splinter FK., and Winnefeld K.: Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch Toxicol 71, 677-683, 1997.
34. Miller TR., Anderson RJ., Linas SL., Henrich WL., Berns AS, et al.: Urinary diagnostic indices in acute renal failure: a prospective study. Ann Intern Med 89, 47-50, 1978.
35. Szeto HH., Inturrisi CE., Houde R., Saal S., Cheigh J, et al.: Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. Ann Intern Med 86, 738-741, 1977.
36. Zager RA., Gmur DJ., Bredl CR., and Eng MJ.: Degree and time sequence of hypothermic protection against experimental ischemic acute renal failure. Circ Res 65, 1263-1269, 1989.
37. Mitch WE., Walser M., Buffington GA., and Lemann J Jr.: A simple method of estimating progression of chronic renal failure. Lancet 2, 1326-1328, 1976.
38. Shulman NB., Ford CE., Hall WD., Blaufox MD., Simon D, et al.: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 13 (5 Suppl), I80-I93, 1989.
39. Kruidering M., Van de Water B., de Heer E., Mulder GJ., and Nagelkerke JF.: Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther 280, 638-649, 1997.
40. Davis CA., Nick HS., and Agarwal A.: Manganese superoxide dismutase attenuates Cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol 12, 2683-2690, 2001.
41. Richter C., Gogvadze V., Laffranchi R., Schlapbach R., Schweizer M, et al.: Oxidants in mitochondria: from physiology to diseases. Biochim Biophys Acta 1271, 67-74, 1995.
42. Benard P., Desplanches G., Macquet JP., and Simon J.: Whole-body autoradiographic study of the distribution of 195mPt in healthy and tumor-bearing mice treated with labeled cisplatin. Cancer Treat Rep 67, 457-466, 1983.
43. Siddik ZH., Newell DR., Boxall FE., and Harrap KR.: The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 36, 1925-1932, 1987.
44. Chen Q., Espey MG., Sun AY., Lee JH., Krishna MC, et al.: Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 104, 8749-8754, 2007.
45. Frei B. and Lawson S.: Vitamin C and cancer revisited. Proc Natl Acad Sci USA 105, 11037-11038, 2008.
46. Knowles HJ., Raval RR., Harris AL., and Ratcliffe PJ.: Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res 63, 1764-1768, 2003.
47. Yeom CH., Lee G., Park JH., Yu J., Park S, et al.: High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med 7, 70, 2009.
48. Chen Q., Espey MG., Sun AY., Pooput C., Kirk KL, et al.: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 105, 11105-11109, 2008.
49. Lee KW., Lee HJ., Surh YJ., and Lee CY.: Vitamin C and cancer chemoprevention: reappraisal. Am J Clin Nutr 78, 1074-1078, 2003.
50. Fraga CG., Shigenaga MK., Park JW., Degan P., and Ames BN.: Oxidative damage to DNA during aging: 8-hydroxy-2-deoxyguanosine in rat organ DNA and urine. Proc Natl Acad Sci USA 87, 4533-4537, 1990.
51. Murakami A., Nakamura Y., Torikai K., Tanaka T., Koshiba T, et al.: Inhibitory effect of citrus nobiletin on phorbol ester-induced skin inflammation, oxidative stress, and tumor promotion in mice. Cancer Res 60, 5059-5066, 2000.
52. Reagan-Shaw S., Nihal M., and Ahmad N.: Dose translation from animal to human studies revisited. FASEB J 22, 659-661, 2008.
53. Levine M., Wang Y., Padayatty SJ., and Morrow J.: A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci USA 98, 9842-9846, 2001.